Literature DB >> 9666411

New insights in the pathogenesis of rheumatoid arthritis.

F C Breedveld1.   

Abstract

Recent advances in molecular technology as well as clinical research findings have enabled the identification of distinct cell subsets, cell surface markers, and cell products that contribute to the immune mediated inflammation observed in rheumatoid arthritis (RA). However, the lack of definitive insight into the disease etiology has resulted in various hypotheses about the roles of these cells or molecules in the pathophysiology of RA. This review summarizes arguments for and against the central role played by T cells in the initiation and perpetuation of RA. Although the available data do not exclude a role of any particular inflammatory mechanism, understanding of immunoregulatory functions of various T cell subsets may lead to more targeted and effective interventions.

Entities:  

Mesh:

Year:  1998        PMID: 9666411

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  9 in total

Review 1.  Treatment advances in rheumatoid arthritis.

Authors:  E R Arriola; N P Lee
Journal:  West J Med       Date:  1999-05

Review 2.  A review of immunologic diseases of the dog.

Authors:  N C Pedersen
Journal:  Vet Immunol Immunopathol       Date:  1999-08-02       Impact factor: 2.046

3.  IL-1 beta- and IL-4-induced down-regulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA).

Authors:  A Kehlen; R Lauterbach; A N Santos; K Thiele; U Kabisch; E Weber; D Riemann; J Langner
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

Review 4.  Leflunomide: mode of action in the treatment of rheumatoid arthritis.

Authors:  F C Breedveld; J M Dayer
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

5.  Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis.

Authors:  A Kehlen; K Thiele; D Riemann; J Langner
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

6.  Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro.

Authors:  R L Van Bezooijen; L Van Der Wee-Pals; S E Papapoulos; C W G M Löwik
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

7.  Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures.

Authors:  O Elkayam; I Yaron; I Shirazi; R Judovitch; D Caspi; M Yaron
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

8.  Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism.

Authors:  Sridar V Chittur; Niquiche Sangster-Guity; Paulette J McCormick
Journal:  BMC Genomics       Date:  2008-10-29       Impact factor: 3.969

9.  Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice.

Authors:  David J Shealy; Paul H Wooley; Eva Emmell; Amy Volk; Amy Rosenberg; George Treacy; Carrie L Wagner; Lois Mayton; Don E Griswold; Xiao-Yu R Song
Journal:  Arthritis Res       Date:  2002-06-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.